CYLTEZO Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count)
RxNorm 2680757

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2680757 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: CYLTEZO Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count).

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
CYLTEZO Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count)
AUI:12889297
View
SY
Cyltezo Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count)
AUI:12889296
View
BPCK
{4 (0.4 mL adalimumab-adbm 100 mg/ML Auto-Injector [Cyltezo]) } Pack [Cyltezo Pen 40 mg/0.4 mL Starter Pack - Psoriasis]
AUI:12885752
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
CYLTEZO Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count)
(Atom ID: 12889297)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
CYLTEZO Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2680757
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12889297
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2680757
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Cyltezo Pen 40 mg/0.4 mL Starter Pack - Psoriasis/Uveitis (4 count)
(Atom ID: 12889296)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Cyltezo Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2680757
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12889296
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2680757
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
BPCKPrescribable

Brand Name Pack (BPCK):
{4 (0.4 mL adalimumab-adbm 100 mg/ML Auto-Injector [Cyltezo]) } Pack [Cyltezo Pen 40 mg/0.4 mL Starter Pack - Psoriasis]
(Atom ID: 12885752)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{4 (0.4 ML adalimumab-adbm 100 MG/ML Auto-Injector [Cyltezo]) } Pack [Cyltezo Pen 40 MG/0.4 ML Starter Pack - Psoriasis]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2680757
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12885752
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
2680757
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans